Typhoid fever, a severe illness that has plagued humanity for millennia, is once again raising global alarms . While often viewed as an issue primarily affecting developing nations, health experts warn that the bacterium responsible for the disease is rapidly mutating . The steady rise of antibiotic-resistant typhoid is leaving medical professionals with a shrinking list of effective treatments, transforming this ancient killer into a modern global health crisis .
Caused by the bacterium Salmonella enterica serovar Typhi, typhoid fever spreads mainly through the consumption of contaminated food and water . Currently, antibiotics are the only viable treatment for infected individuals . However, a landmark 2022 study published in The Lancet Microbe revealed that extensively drug-resistant, or XDR, strains are quickly replacing non-resistant variations of the disease . This alarming trend has sparked an urgent global race to expand vaccination programs and develop new diagnostic tools .
The Rise of Extensively Drug-Resistant Strains
To understand the scope of the problem, researchers sequenced 3,489 genomic strains collected between 2014 and 2019 from patients in India, Nepal, Bangladesh, and Pakistan . The results demonstrated a sharp, dangerous increase in XDR typhoid . These highly evolved bacterial strains are completely impervious to frontline antibiotics such as ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole . Furthermore, they are also growing increasingly resistant to newer medical interventions, including fluoroquinolones and third-generation cephalosporins .
The most concerning development involves azithromycin, which currently stands as the last widely effective oral antibiotic available for typhoid treatment . Scientists have identified spreading mutations that confer resistance to this crucial medication . While these specific mutations have not yet fully merged with XDR strains, experts warn that if they do, it will threaten the efficacy of all oral antimicrobials . If this happens, treatment options will become severely restricted .
A Rapidly Spreading Global Threat
Today, antimicrobial resistance is one of the leading causes of death worldwide, claiming more lives annually than HIV/AIDS or malaria . Although South Asia currently accounts for approximately 70 percent of all global typhoid cases, the disease is no longer confined to specific borders . Since 1990, researchers have recorded nearly 200 instances of international spread . Extensively drug-resistant strains have been exported to Southeast Asia, East and Southern Africa, and even nations like the United Kingdom, the United States, and Canada .
The speed of this transmission is unprecedented . The first XDR typhoid strain was identified in Pakistan in 2016, and by 2019, it had become the dominant genotype in the country . In 2024 alone, over 13 million cases of typhoid were reported worldwide . Without effective treatment, up to 20 percent of these cases can be fatal . According to Stanford University infectious disease researcher Jason Andrews, the rapid emergence of these highly resistant strains highlights an urgent need for preventive measures, especially in the most vulnerable nations .
Advancing Point-of-Care Diagnostics
To combat the spread, the medical community is investing heavily in better detection methods . Recently, CARB-X awarded $1.8 million to Chembio Diagnostic Systems to develop a rapid, point-of-care test for typhoid fever . This new diagnostic tool aims to use a simple fingerstick blood sample to detect Immunoglobulin A (IgA) antibodies .
By targeting specific biomarkers associated with acute infection rather than previous exposure or vaccination, this test promises higher diagnostic accuracy than current rapid tests . If successful, this innovation could dramatically improve clinical decision-making in low- and middle-income countries where traditional laboratory infrastructure is often limited or unavailable .
Expanding Access to Lifesaving Vaccines
With antibiotic options dwindling, public health officials are increasingly relying on typhoid conjugate vaccines to prevent outbreaks before they begin . The World Health Organization has prequalified four of these vaccines, and global rollout efforts reached a major milestone recently . In 2025 alone, over 80 million children received the vaccine during introduction campaigns in Burkina Faso, Kenya, Bangladesh, and Niger .
Countries that adopted the vaccine earlier are already seeing remarkable results . Pakistan became the first nation to introduce routine typhoid immunization in 2019, vaccinating over 30 million children . Recent data shows this effort caused typhoid incidence to plummet by 49 percent in the Sindh province and 66 percent in the Punjab province within the first two years . Other nations are also stepping up, such as Fiji, which prioritized disease surveillance through improved reporting and contact tracing following a mass vaccination campaign .
Similarly, a 2021 modeling study in India estimated that vaccinating children in urban areas could prevent up to 36 percent of cases and deaths . As Dr. Vijayalaxmi Mogasale noted, tackling the threat of antibiotic-resistant typhoid does not rely exclusively on developing new medicines . Instead, the solution demands responsible antibiotic use combined with prioritizing preventive vaccines across high-burden regions to ensure this ancient disease does not trigger a future global health catastrophe .
